Gilead Sciences, Inc. (GILD) Presents at Jefferies London Healthcare Conference 2025 Transcript

Core Insights - Gilead has experienced significant growth in its base business over the past three years, indicating the start of a long growth cycle for the company [2] - The company has diversified its operations into various therapeutic areas, including virology, HIV, oncology, and inflammation, which has begun to yield positive results [3] Financial Performance - Base revenues, excluding COVID antiviral sales, grew by 7% year-over-year in 2023, following an 8% growth in the previous year [4] - Despite facing a $1.1 billion headwind from Medicare Part D reform, the company’s base business is projected to grow by 9% to 10%, with a current growth rate of 5% [4]